Thomas Kitzing

2.8k total citations · 1 hit paper
22 papers, 1.9k citations indexed

About

Thomas Kitzing is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Thomas Kitzing has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Cell Biology and 8 papers in Oncology. Recurrent topics in Thomas Kitzing's work include Cellular Mechanics and Interactions (7 papers), Cell Adhesion Molecules Research (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Thomas Kitzing is often cited by papers focused on Cellular Mechanics and Interactions (7 papers), Cell Adhesion Molecules Research (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Thomas Kitzing collaborates with scholars based in Germany, United States and United Kingdom. Thomas Kitzing's co-authors include Robert Grosse, Scott W. Lowe, Dominique T. Brandt, Johannes Zuber, Darjus F. Tschaharganeh, Johanna Ivaska, O. Fackler, Sebastian Hannemann, Susann Weissmueller and John W. Copeland and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Thomas Kitzing

21 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

2014 362 citations Susann Weissmueller, Eusebio Manchado et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Kitzing Germany	16	1.2k	613	584	358	227	22	1.9k
Corinne Reimer United States	23	1.4k 1.2×	460 0.8×	456 0.8×	441 1.2×	254 1.1×	52	2.1k
Ana Cerezo Spain	13	1.1k 0.9×	677 1.1×	841 1.4×	358 1.0×	146 0.6×	16	2.0k
Emma T. Bowden United States	17	1.1k 0.9×	619 1.0×	407 0.7×	319 0.9×	330 1.5×	25	1.8k
Weon‐Kyoo You South Korea	19	935 0.8×	277 0.5×	522 0.9×	365 1.0×	181 0.8×	37	1.7k
Juha Rantala Finland	19	1.3k 1.0×	362 0.6×	440 0.8×	455 1.3×	200 0.9×	45	1.8k
John M. Lamar United States	21	1.2k 1.0×	1.1k 1.8×	649 1.1×	384 1.1×	404 1.8×	38	2.3k
Bradford W. Ozanne United Kingdom	20	1.1k 0.9×	580 0.9×	537 0.9×	199 0.6×	371 1.6×	28	1.8k
Yaara Zwang Israel	17	1.5k 1.3×	709 1.2×	645 1.1×	282 0.8×	63 0.3×	19	2.1k
Dominique Grall France	18	961 0.8×	378 0.6×	386 0.7×	280 0.8×	408 1.8×	29	1.7k
Chitose Oneyama Japan	29	1.6k 1.3×	378 0.6×	327 0.6×	493 1.4×	166 0.7×	61	2.1k

Countries citing papers authored by Thomas Kitzing

Since Specialization

Citations

This map shows the geographic impact of Thomas Kitzing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kitzing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kitzing more than expected).

Fields of papers citing papers by Thomas Kitzing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kitzing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kitzing. The network helps show where Thomas Kitzing may publish in the future.

Co-authorship network of co-authors of Thomas Kitzing

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kitzing. A scholar is included among the top collaborators of Thomas Kitzing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kitzing. Thomas Kitzing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reck, Martin, K. Syrigos, Skaidrius Miliauskas, et al.. (2024). A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNIS. Translational Lung Cancer Research. 13(12). 3364–3381.

Johnson, Melissa L., Eelke Gort, Shubham Pant, et al.. (2021). 524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis. Annals of Oncology. 32. S591–S592. 23 indexed citations

Lenz, Heinz‐Josef, Guillem Argilés, Takayuki Yoshino, et al.. (2020). Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Clinical Colorectal Cancer. 20(1). 84–95.e8. 13 indexed citations

Reck, Martin, Kostas Syrigos, Skaidrius Miliauskas, et al.. (2020). Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. Lung Cancer. 148. 159–165. 18 indexed citations

Gort, Eelke, Melissa L. Johnson, Jimmy J. Hwang, et al.. (2020). A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3651–TPS3651. 29 indexed citations

Grosso, Federica, Nicola Steele, Anna K. Nowak, et al.. (2018). 213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study. Journal of Thoracic Oncology. 13(4). S128–S128. 1 indexed citations

Reck, Martin, A.J. Staal-van den Brekel, Anders Mellemgaard, et al.. (2017). Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study. Annals of Oncology. 28. v494–v494. 1 indexed citations

Zhao, Zhen, Chi-Chao Chen, Cory D. Rillahan, et al.. (2015). Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics. 47(5). 539–543. 24 indexed citations

Weissmueller, Susann, Eusebio Manchado, Michael Saborowski, et al.. (2014). Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling. Cell. 157(2). 382–394. 362 indexed citations breakdown →

10.

Chen, Chong, Yu Liu, Amy Rappaport, et al.. (2014). MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell. 25(5). 652–665. 230 indexed citations

11.

Huang, Chun‐Hao, Amaia Lujambio, Johannes Zuber, et al.. (2014). CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development. 28(16). 1800–1814. 150 indexed citations

12.

Xue, Wen, Thomas Kitzing, Stéphanie Roessler, et al.. (2012). A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proceedings of the National Academy of Sciences. 109(21). 8212–8217. 107 indexed citations

13.

Kitzing, Thomas, et al.. (2011). Nucleating actin for invasion. Nature reviews. Cancer. 11(3). 177–187. 211 indexed citations

14.

Kitzing, Thomas, Ying Wang, Olivier Pertz, John W. Copeland, & Robert Grosse. (2010). Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene. 29(16). 2441–2448. 114 indexed citations

15.

März, Martin, et al.. (2009). Detection of activated Rho in fixed Xenopus tissue. Developmental Dynamics. 238(6). 1407–1411. 8 indexed citations

16.

Brandt, Dominique T., Christian Baarlink, Thomas Kitzing, et al.. (2009). SCAI acts as a suppressor of cancer cell invasion through the transcriptional control of β1-integrin. Nature Cell Biology. 11(5). 557–568. 109 indexed citations

17.

Pellinen, Teijo, Saara Hämälistö, Antti Arjonen, et al.. (2008). Integrin Trafficking Regulated by Rab21 Is Necessary for Cytokinesis. Developmental Cell. 15(3). 371–385. 159 indexed citations

18.

Hannemann, Sebastian, Ricardo Madrid, Jana Šťastná, et al.. (2008). The Diaphanous-related Formin FHOD1 Associates with ROCK1 and Promotes Src-dependent Plasma Membrane Blebbing. Journal of Biological Chemistry. 283(41). 27891–27903. 60 indexed citations

19.

Kitzing, Thomas, Dominique T. Brandt, Sebastian Hannemann, et al.. (2007). Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. Genes & Development. 21(12). 1478–1483. 138 indexed citations

20.

Kitzing, Thomas, et al.. (2005). Gα12/13 Is Essential for Directed Cell Migration and Localized Rho-Dia1 Function. Journal of Biological Chemistry. 280(51). 42242–42251. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact